HealthQuill Clinical trials
Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive top-line results” on the efficacy and safety of the treatment in adults, according to the company.
Drugs Health Pharma

Merck’s oral pill for bad cholesterol shows ‘positive’ data during trials

HQ Team June 10, 2025: Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive.

Read More
The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV) in infants up to one year of age for the first RSV season.
Drugs Health Pharma

Merck & Co.’s RSV injection for infants gets nod from US drug regulator

HQ Team June 10, 2025: The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV).

Read More
A third of patients with a type of blood cancer, especially those whose disease had returned or not responded to other treatments, have shown “promising” results in an early Johnson & Johnson trial.
Drugs Health Pharma

A third of blood cancer cases in J&J trials live without detectable cancer 

HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not.

Read More
US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation of an immunotherapy candidate to treat multiple tumour types.
Drugs Health Pharma

Bristol, BioNTech in $11.1b pact for immunotherapy candidate

HQ Team June 2, 2025: US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation.

Read More
Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.
Drugs Health Pharma

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

Read More
The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the late-stage development of a bird flu vaccine for humans.
Drugs Health Pharma

US terminates Moderna contract for investigational bird flu vaccine

HQ Team May 29, 2025: The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the.

Read More
GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract infections after the study achieved its goal on efficacy.
Drugs Health Pharma

GSK, Sepro end trial for oral drug to treat urinary tract infections

 HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.

Read More
Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.
Drugs Health Pharma

Eli Lilly to buy SiteOne to grab test inhibitor to treat chronic pain

HQ Team May 28, 2025: Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor.

Read More
The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.

Read More
GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2 billion in cash.
Drugs Health Pharma

GSK to buy Boston’s lead drug asset for liver disease for $2 billion in cash

HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2.

Read More